SK13312001A3 - Spôsob prípravy stabilnej nehygroskopickej soli L(-)-karnitínu, granulát alebo prášok s obsahom kyslého fumarátu L(-)-karnitínu - Google Patents
Spôsob prípravy stabilnej nehygroskopickej soli L(-)-karnitínu, granulát alebo prášok s obsahom kyslého fumarátu L(-)-karnitínu Download PDFInfo
- Publication number
- SK13312001A3 SK13312001A3 SK1331-2001A SK13312001A SK13312001A3 SK 13312001 A3 SK13312001 A3 SK 13312001A3 SK 13312001 A SK13312001 A SK 13312001A SK 13312001 A3 SK13312001 A3 SK 13312001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- carnitine
- granulate
- powder
- mass
- weight
- Prior art date
Links
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical class C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 150000003839 salts Chemical class 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 29
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 17
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 12
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- 239000001530 fumaric acid Substances 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000002425 crystallisation Methods 0.000 claims description 10
- 230000008025 crystallization Effects 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 238000000227 grinding Methods 0.000 claims description 9
- 238000007711 solidification Methods 0.000 claims description 9
- 230000008023 solidification Effects 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 239000001358 L(+)-tartaric acid Substances 0.000 claims description 6
- 235000011002 L(+)-tartaric acid Nutrition 0.000 claims description 6
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000003999 initiator Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 235000011837 pasties Nutrition 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012297 crystallization seed Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI000551A IT1312018B1 (it) | 1999-03-19 | 1999-03-19 | Procedimento migliorato per la produzione di sali non igroscopicidella l(-)-carnitina. |
| PCT/EP2000/002344 WO2000056701A1 (en) | 1999-03-19 | 2000-03-16 | An improved process for the preparation of non-hygroscopic salts of l(-)-carnitine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK13312001A3 true SK13312001A3 (sk) | 2002-05-09 |
Family
ID=11382333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1331-2001A SK13312001A3 (sk) | 1999-03-19 | 2000-03-16 | Spôsob prípravy stabilnej nehygroskopickej soli L(-)-karnitínu, granulát alebo prášok s obsahom kyslého fumarátu L(-)-karnitínu |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6372940B1 (cs) |
| EP (1) | EP1163207B1 (cs) |
| JP (1) | JP2002540094A (cs) |
| KR (1) | KR100664560B1 (cs) |
| CN (1) | CN1147462C (cs) |
| AR (1) | AR023101A1 (cs) |
| AT (1) | ATE247627T1 (cs) |
| AU (1) | AU4105800A (cs) |
| CA (1) | CA2359106A1 (cs) |
| CZ (1) | CZ299312B6 (cs) |
| DE (1) | DE60004649T2 (cs) |
| DK (1) | DK1163207T3 (cs) |
| ES (1) | ES2204555T3 (cs) |
| HK (1) | HK1042468A1 (cs) |
| HU (1) | HUP0200402A3 (cs) |
| IT (1) | IT1312018B1 (cs) |
| NZ (1) | NZ512640A (cs) |
| PL (1) | PL199614B1 (cs) |
| PT (1) | PT1163207E (cs) |
| SI (1) | SI1163207T1 (cs) |
| SK (1) | SK13312001A3 (cs) |
| WO (1) | WO2000056701A1 (cs) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2631569B1 (fr) * | 1988-05-20 | 1990-07-27 | Renault Automation | Detecteur de proximite magnetique destine notamment a la decoupe laser |
| ITRM20010030A1 (it) * | 2001-01-23 | 2002-07-23 | Aldo Fassi | Sali di carnitine utili come integratori dietetici/nutrizionali o come farmaci, composizioni che li contengono e procedimenti per la loro pr |
| RS55023B1 (sr) * | 2001-02-24 | 2016-11-30 | Boehringer Ingelheim Pharma | Derivati ksantina, njihovo dobijanje i njihova primena kao lekova |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| CN101209975B (zh) * | 2006-12-29 | 2010-12-01 | 沈阳科硕营养科技有限公司 | 左旋肉碱富马酸钙及其制备方法与用途 |
| KR101610005B1 (ko) * | 2007-08-17 | 2016-04-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체 |
| PE20140960A1 (es) * | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| AU2009281122C1 (en) * | 2008-08-15 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
| EP2344195A2 (en) | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| NZ592924A (en) | 2008-12-23 | 2014-05-30 | Boehringer Ingelheim Int | Salt forms of a xanthine derivative |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
| EP2425834A1 (en) * | 2010-09-06 | 2012-03-07 | Lonza Ltd. | Process for the production of l-carnitine tartrate |
| JP2012092036A (ja) * | 2010-10-26 | 2012-05-17 | Mitsubishi Rayon Co Ltd | カルニチンの塩の製造方法 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| CN103781788B (zh) | 2011-07-15 | 2016-08-17 | 勃林格殷格翰国际有限公司 | 经取代的喹唑啉、其制备及其在药物组合物中的用途 |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| ES2929025T3 (es) | 2012-05-14 | 2022-11-24 | Boehringer Ingelheim Int | Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US20140316156A1 (en) * | 2013-04-18 | 2014-10-23 | Deborah Warner | Method of producing therapeutic agent |
| JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害薬の医学的使用 |
| KR102391564B1 (ko) | 2016-06-10 | 2022-04-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴 및 메트포르민의 병용물 |
| CN106748845B (zh) * | 2016-12-23 | 2018-11-20 | 东北制药集团股份有限公司 | 一种左旋肉碱盐微粉的制备方法 |
| KR20190017310A (ko) | 2017-08-10 | 2019-02-20 | 주식회사 셀트리온화학연구소 | 약제학적 성질이 개선된 l-카르니틴 화합물의 염, 이의 제조방법, 이를 함유하는 약학 조성물 |
| JP6964876B2 (ja) * | 2017-11-27 | 2021-11-10 | 株式会社古川リサーチオフィス | オロット酸−カルニチン混合体粉体又はフマル酸−カルニチン混合体粉体の製造方法 |
| CN108383741A (zh) * | 2018-03-16 | 2018-08-10 | 开原亨泰化工有限公司 | 一种制备左旋肉碱成盐的新方法 |
| CN109096129B (zh) * | 2018-09-30 | 2021-04-27 | 东北制药集团股份有限公司 | 一种左旋肉碱酒石酸盐的制备方法 |
| CN109535022B (zh) * | 2018-11-12 | 2022-03-01 | 天津大学 | 一种提高左旋肉碱富马酸盐流动性的制备方法 |
| US20240217920A1 (en) * | 2022-12-28 | 2024-07-04 | Hubei Xujie Pharmaceutical Co., Ltd. | Process for producing l-carnitine |
| US20240228429A1 (en) * | 2023-01-04 | 2024-07-11 | Hubei Xujie Pharmaceutical Co., Ltd | Process for producing l-carnitine |
| CN118638020B (zh) * | 2024-08-08 | 2024-11-19 | 杭州海尔希畜牧科技有限公司 | L-天门冬氨酸l(-)肉碱(1:1)的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1172394B (it) * | 1983-12-28 | 1987-06-18 | Sigma Tau Ind Farmaceuti | Sali della l-carnitina e di alcuni alcanoil derivati della l-carnitina e procedimento per la loro preparazione |
| DE3463261D1 (en) * | 1983-12-28 | 1987-05-27 | Sigma Tau Ind Farmaceuti | Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same |
| US5073376A (en) * | 1989-12-22 | 1991-12-17 | Lonza Ltd. | Preparations containing l-carnitine |
| IT1289974B1 (it) * | 1997-02-25 | 1998-10-19 | Aldo Fassi | Procedimento per la produzione di sali stabili e non igroscopici di l(-)carnitina e di alcanoli l(-)-carnitine |
| EE03604B1 (et) * | 1996-05-31 | 2002-02-15 | Fassi Aldo | L(-)-karnitiini ja alkanoüül-L(-)-karnitiini stabiilsed mittehügroskoopsed soolad, nende valmistamismeetod ja neid sooli sisaldavad tahked peroraalselt manustatavad kompositsioonid |
-
1999
- 1999-03-19 IT IT1999MI000551A patent/IT1312018B1/it active
-
2000
- 2000-03-16 AT AT00920506T patent/ATE247627T1/de not_active IP Right Cessation
- 2000-03-16 JP JP2000606564A patent/JP2002540094A/ja not_active Ceased
- 2000-03-16 EP EP00920506A patent/EP1163207B1/en not_active Expired - Lifetime
- 2000-03-16 AU AU41058/00A patent/AU4105800A/en not_active Abandoned
- 2000-03-16 CZ CZ20013376A patent/CZ299312B6/cs not_active IP Right Cessation
- 2000-03-16 CN CNB008034001A patent/CN1147462C/zh not_active Expired - Fee Related
- 2000-03-16 PT PT00920506T patent/PT1163207E/pt unknown
- 2000-03-16 HU HU0200402A patent/HUP0200402A3/hu unknown
- 2000-03-16 SI SI200030176T patent/SI1163207T1/xx unknown
- 2000-03-16 SK SK1331-2001A patent/SK13312001A3/sk unknown
- 2000-03-16 DE DE60004649T patent/DE60004649T2/de not_active Expired - Lifetime
- 2000-03-16 ES ES00920506T patent/ES2204555T3/es not_active Expired - Lifetime
- 2000-03-16 HK HK02104080.1A patent/HK1042468A1/zh unknown
- 2000-03-16 NZ NZ512640A patent/NZ512640A/xx unknown
- 2000-03-16 KR KR1020017010602A patent/KR100664560B1/ko not_active Expired - Fee Related
- 2000-03-16 CA CA002359106A patent/CA2359106A1/en not_active Abandoned
- 2000-03-16 PL PL349894A patent/PL199614B1/pl not_active IP Right Cessation
- 2000-03-16 DK DK00920506T patent/DK1163207T3/da active
- 2000-03-16 WO PCT/EP2000/002344 patent/WO2000056701A1/en active IP Right Grant
- 2000-03-16 US US09/868,980 patent/US6372940B1/en not_active Expired - Fee Related
- 2000-03-17 AR ARP000101222A patent/AR023101A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0200402A3 (en) | 2002-11-28 |
| KR20010102288A (ko) | 2001-11-15 |
| HK1042468A1 (zh) | 2002-08-16 |
| EP1163207B1 (en) | 2003-08-20 |
| CZ20013376A3 (cs) | 2002-02-13 |
| JP2002540094A (ja) | 2002-11-26 |
| ITMI990551A1 (it) | 2000-09-19 |
| DE60004649T2 (de) | 2004-03-18 |
| ES2204555T3 (es) | 2004-05-01 |
| IT1312018B1 (it) | 2002-04-04 |
| CA2359106A1 (en) | 2000-09-28 |
| KR100664560B1 (ko) | 2007-01-03 |
| AR023101A1 (es) | 2002-09-04 |
| AU4105800A (en) | 2000-10-09 |
| NZ512640A (en) | 2003-03-28 |
| WO2000056701A1 (en) | 2000-09-28 |
| PL199614B1 (pl) | 2008-10-31 |
| DK1163207T3 (da) | 2003-12-01 |
| CN1339023A (zh) | 2002-03-06 |
| CN1147462C (zh) | 2004-04-28 |
| HUP0200402A2 (hu) | 2002-05-29 |
| SI1163207T1 (en) | 2003-12-31 |
| CZ299312B6 (cs) | 2008-06-18 |
| US6372940B1 (en) | 2002-04-16 |
| PT1163207E (pt) | 2003-12-31 |
| EP1163207A1 (en) | 2001-12-19 |
| ATE247627T1 (de) | 2003-09-15 |
| DE60004649D1 (de) | 2003-09-25 |
| PL349894A1 (en) | 2002-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK13312001A3 (sk) | Spôsob prípravy stabilnej nehygroskopickej soli L(-)-karnitínu, granulát alebo prášok s obsahom kyslého fumarátu L(-)-karnitínu | |
| AU2002355624B2 (en) | Crystalline composition containing escitalopram | |
| RU2106140C1 (ru) | Фармацевтическая композиция, способ ее получения, физическая форма n-[4-[5-(циклопентилоксикарбонил)амино-1-метилиндол-3-ил-метил]-3-метоксибензоил]-2-метилбензолсульфонамида, способы ее получения | |
| AU750978B2 (en) | Polymorphic crystalline forms of celecoxib | |
| ME00517B (me) | Atorvastati kalcijum u farmaceutskom obliku, njegovoj smješi i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum | |
| FI112030B (fi) | Menetelmä S(+)-ibuprofeeni-partikkeleiden valmistamiseksi | |
| CN107176923A (zh) | 拉奎尼莫钠晶体及其制备方法 | |
| KR20030024833A (ko) | 시탈로프람을 함유하는 약학 조성물 | |
| CN104829622A (zh) | 一种枸橼酸西地那非化合物及其药物组合物 | |
| JPH08502505A (ja) | オルトリン酸二水素チリジン、その製造方法及びそれを含む薬剤 | |
| UA80092C2 (en) | Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition | |
| CA2626242A1 (en) | Polymorph transformation of zolpidem in tablet matrix | |
| CN117045608A (zh) | 一种维生素b2的速释制剂及制备方法 | |
| RU2183119C1 (ru) | Фармацевтическая композиция, обладающая спазмолитической активностью, способ ее получения | |
| JP2004010575A (ja) | 溶解性を改善した医薬組成物 | |
| JPH0674232B2 (ja) | 粒状プロピオン酸ナトリウムの製造方法 | |
| CA2413578C (en) | Use of dicalcium phosphate anhydride powder | |
| AU2002236157B2 (en) | Pharmaceutical formulation comprising atorvastatin calcium | |
| CN101492435A (zh) | 含有依地普仑草酸盐的结晶组合物 | |
| AU2002236157A1 (en) | Pharmaceutical formulation comprising atorvastatin calcium |